OMD

Osteoadherin (OMD/osteomodulin) is a mineralized-tissue small leucine-rich proteoglycan that couples cell adhesion to matrix mineralization in bone and tooth (PMID:9566981, PMID:9642227). Originally isolated from bovine bone as a keratan sulfate proteoglycan that binds hydroxyapatite and promotes osteoblast attachment as efficiently as fibronectin, it engages cells through the integrin αvβ3, the only integrin recovered by osteoadherin affinity chromatography (PMID:9566981). Its primary structure comprises a central array of leucine-rich repeats, a uniquely acidic C-terminal domain, N-linked glycosylation sites, and tyrosine sulfation sites, with mineralized-tissue-restricted expression (PMID:9642227). The tyrosine sulfate-rich N-terminal domain sequesters heparin-binding ligands including bFGF-2, thrombospondin I, MMP13, the NC4 domain of collagen IX, and interleukin-10, with affinity scaling with the number and position of sulfated tyrosines (PMID:19700767). Functionally, OMD drives osteoblast maturation: gain and loss of function reciprocally control alkaline phosphatase activity, mineralization, and differentiation marker expression while restraining proliferation and migration (PMID:18496725), and it limits osteoblast apoptosis by suppressing caspase 3/7 activity (PMID:31638177). Transcriptionally, OMD is differentially controlled by TGF-β family signaling—downregulated by TGF-β1 and upregulated by BMP-2 via Smad1/Smad4 acting on its promoter (PMID:16970923, PMID:31638177)—and is induced by ATF4, which in vascular smooth muscle drives OMD-dependent PI3K/AKT activation and osteogenic calcification (PMID:41274065). OMD concentrates at the mineralization front in bone and predentin, co-distributing with bone sialoprotein and collagen fibers, with distinct mineral-bound (increasingly keratan sulfate-substituted) and non-mineral-bound (keratan sulfate-poor) pools produced during bone formation (PMID:23337037, PMID:22355375, PMID:12384815). A recurrent t(9;17) translocation places the OMD promoter upstream of USP6 coding sequences to generate an OMD-USP6 fusion oncogene in aneurysmal bone cyst (PMID:15735689).

1. 1998 High

   Established OMD as a distinct bone matrix proteoglycan and identified its adhesive mechanism, answering what molecule mediates osteoblast attachment to mineralized matrix.

   Evidence Protein purification from bovine bone, hydroxyapatite binding, integrin affinity pulldown, and cell attachment assays; cDNA sequencing with Northern blot and in situ hybridization

   PMID:9566981 PMID:9642227

   Open questions at the time

   • No structural model of the LRR-integrin interface
   • Functional role of the unique acidic C-terminal domain not tested
   • In vivo requirement for adhesion not established by knockout
2. 2002 Medium

   Localized OMD to the bone mineralization front alongside bone sialoprotein, indicating a spatial role in directing mineral deposition.

   Evidence Quantitative immunogold electron microscopy with double labeling in rat bone

   PMID:12384815

   Open questions at the time

   • Co-distribution with BSP does not demonstrate functional cooperation
   • No causal test of OMD effect on mineral nucleation in vivo
3. 2002 Medium

   Showed TGF-β1 regulates OMD synthesis in odontoblasts, linking the proteoglycan to dental matrix signaling.

   Evidence Immunohistochemistry and RT-PCR with TGF-β1 stimulation of tooth slice and explant cultures

   PMID:12489179

   Open questions at the time

   • Direction of regulation in dental cells differs in context from bone studies
   • Promoter elements mediating the response not mapped here
4. 2006 Medium

   Defined OMD as a transcriptional target differentially controlled by TGF-β versus BMP signaling, clarifying how its expression is positioned in osteogenic pathways.

   Evidence In silico promoter analysis, reporter assays, qRT-PCR with TGF-β1 and BMP-2 treatment

   PMID:16970923

   Open questions at the time

   • Direct Smad/AP-1 promoter occupancy not shown by ChIP
   • Opposing TGF-β/BMP effects mechanism unresolved
5. 2008 Medium

   Demonstrated OMD functionally promotes osteoblast differentiation rather than merely marking it, via reciprocal gain/loss of function.

   Evidence Stable OSAD overexpression and shRNA knockdown in MC3T3-E1 with ALP, mineralization, and marker assays

   PMID:18496725

   Open questions at the time

   • Single cell line, single lab
   • Molecular mediator linking OMD to differentiation gene program unknown
6. 2009 Medium

   Identified the tyrosine sulfate-rich N-terminal domain as a sulfation-dependent docking site for heparin-binding effectors, providing a mechanism for growth factor/cytokine/protease sequestration.

   Evidence Solid-phase binding assays and ion-exchange fractionation of N-terminal fragments against multiple partners

   PMID:19700767

   Open questions at the time

   • Binding shown in vitro; physiological sequestration not demonstrated in tissue
   • Functional consequences of each ligand interaction untested
7. 2012 Medium

   Refined dental localization to predentin and the mineralization front in association with collagen, with induction following matrix maturation.

   Evidence Immunohistochemistry, quantitative immunogold EM, and gene expression in mineralizing dental pulp cells

   PMID:22355375

   Open questions at the time

   • Collagen association not mapped to a binding domain
   • Causal role in dentin mineralization not tested
8. 2013 Medium

   Revealed regulated glycosylation generating distinct mineral-bound versus non-mineral-bound OMD pools, suggesting glycoform-specific roles in mineralization.

   Evidence Sequential enzymatic digestion, Western blot, gene expression, and microscopy of mineral/non-mineral fractions during endochondral bone formation

   PMID:23337037

   Open questions at the time

   • Functional difference between glycoforms not directly tested
   • Enzymes controlling keratan sulfate substitution unidentified
9. 2019 Medium

   Placed OMD downstream of BMP2/Smad signaling as a suppressor of osteoblast apoptosis, extending its role beyond differentiation.

   Evidence Overexpression/siRNA with caspase 3/7 and viability assays, BMP2 induction, and Smad1/Smad4 promoter reporter assays

   PMID:31638177

   Open questions at the time

   • Anti-apoptotic effector pathway downstream of OMD not defined
   • Single cell line context
10. 2025 Medium

    Connected ATF4-driven OMD expression to PI3K/AKT activation and osteogenic differentiation in vascular calcification, demonstrating OMD function outside skeletal tissue.

    Evidence Transcriptomics, promoter binding validation, in vitro calcification, and in vivo AAV-shATF4 mouse model with pathway Western blots

    PMID:41274065

    Open questions at the time

    • Mechanism linking OMD to PI3K/AKT activation unresolved
    • Direct ATF4 occupancy versus indirect induction not fully separated
11. 2005 Medium

    Identified the OMD locus as a promoter donor in an aneurysmal bone cyst translocation, implicating its tissue-specific expression in driving an oncogenic fusion.

    Evidence Cytogenetic and molecular cloning of t(9;17) breakpoints generating an OMD-USP6 fusion

    PMID:15735689

    Open questions at the time

    • OMD protein function not involved—only its promoter is co-opted
    • Contribution to tumorigenesis is via USP6 overexpression

• Whether OMD is required in vivo for skeletal mineralization and how its glycoform pools and N-terminal ligand sequestration shape the bone microenvironment remain unresolved.
• No knockout/loss-of-function whole-organism phenotype in the corpus
• Physiological consequences of N-terminal heparin-binding ligand sequestration untested
• Functional distinction between mineral-bound and non-mineral-bound glycoforms unestablished